Finance & Acquisitions: Recursion

Parents

2017: Drug discovery startup Recursion raises $60 million in Series B from Data Collective
2017: Lux Capital, which led Recursions Series A round, jumped in again for this round, along with previous participants Obvious Ventures, Advantage Capital, Felicis, Epic, and AME. New investors include Mubadala, Menlo Ventures, CRV, Two Sigma and various
2020: Recursion nabs $239M and an up to $1B partnership with Bayer as AI race heats up
2021: AI drug prospector Recursion bumps IPO up (again) to $374M
2023: Recursion acquires two AI-based drug discovery companies in $87.5M deal
2024: Biotech firm Recursion to buy smaller peer Exscientia for $688 million
2024: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
2024: Recursion, Exscientia Merge to Create AI-Enabled Biotech
2024: Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
2025: How a First-of-its-Kind “Microglia Map” from Recursion and Roche and Genentech Could Unlock New Treatments for Neurodegenerative Diseases
2025: Recursion CEO launches pre-seed fund in response to NIH cuts
6. Recursion Pharmaceuticals
Cyclica
Exscientia Plc (NASDAQ: EXAI)
Valence Discovery